Ipsen, Skyhawk ink deal worth up to $1.8B
- Apr 22, 2024
- 1 min read
Ipsen, Skyhawk Therapeutics pen neurological deal: Ipsen and Skyhawk plan to develop small molecules that can modulate RNA in a deal worth up to $1.8 billion. The upfront payment was not disclosed. The deal focuses on two rare neurological disease targets. Skyhawk is responsible for early research, and Ipsen is responsible for all development after candidate nomination.
I usually spend way too much time thinking of usernames, so finding this name generator made the process much easier. Lots of creative ideas without feeling repetitive.